ENGLEWOOD, Colo., May 22, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").
Ampio has filed Investigative New Drug ("IND") applications for Ampion™ with the FDA and has maintained ongoing dialog with the FDA regarding the Company's development of treatment options which includes inhalation and intravenous applications for COVID-19 affected patients.
Years of extensive in-vitro studies on cell cultures have confirmed that the mechanism of action ("MOA") of Ampion may be suitable for the treatment of inflammatory conditions, such as acute respiratory distress syndrome ("ARDS") and the cytokine storm, associated with COVID-19. Many of these research related findings have been published in peer reviewed, scientific journals, which can be found on the Company's website.